In re Novatel Wireless Securities Litigation

910 F. Supp. 2d 1209, 2012 WL 6644279
Procedural entryThis page is a short order in In re Novatel Wireless Securities Litigation. Read the opinion of the Court — 830 F. Supp. 2d 996
District Court, S.D. California·Decided December 14, 2012·No. Civil No. 08cv1689 AJB (RBB)·Published

Opinion

[1212]*1212ORDER (1) DENYING DEFENDANTS’ MOTION TO EXCLUDE EXPERT TESTIMONY OF BJORN STEIN-HOLT AND (2) AMENDING PLAINTIFFS’ COMPLAINT

[Doc. No. 299]

ANTHONY J. BATTAGLIA, District Judge.

Defendants filed a motion to exclude testimony of Plaintiffs’ expert Bjorn Steinholt on February 15, 2011. (Doc. No. 299.) Based upon the moving papers and arguments and for the reasons set forth herein, Defendants’ motion is hereby DENIED for the reasons set forth below.

Background

Plaintiffs allege that between February 27, 2007, and November 10, 2008 (the “Class Period”), Defendants engaged in a fraudulent scheme to inflate Novatel’s stock value so that Defendants could sell their stock in the company for a profit. (FAC, Doc. No. 23 at ¶¶ 1, 12). Plaintiffs contend that Novatel’s success was largely dependent on its ability to supply wireless modems to its two largest customers, Sprint and Verizon, which in 2006 accounted for 38.2% and 19.7% of Novatel’s revenue respectively. (Id. at ¶ 14). According to Plaintiffs, Defendants “knew that the market was particularly sensitive to information about these customers” and “[s]trong financial results would surely spur an increase in Novatel’s stock price whereas any negative information regarding these customers would reduce it.” (Id. at ¶ 14.)

Plaintiffs allege that throughout the Class Period, Defendants Weinert and Lepando misrepresented the financial condition of the Company because they told investors that the Company was seeing strong demand for its products, and did not disclose to investors that Novatel did not have an adequate “product mix” to meet the needs of its customers. (Id. at ¶¶ 57(a)(iii), 62(a)(ii), 66(a)(ii), 73(a)(ii).) Plaintiffs also allege that Novatel covered up the slowdown in its business by shipping product “early,” which purportedly violated accounting rules governing revenue recognition. (Id. at ¶ 6.) Plaintiffs allege that during this time period, Defendants were selling significant amounts of their Novatel holdings. (Id.) Plaintiffs allege that during the Class Period, Defendants sold 1,258,466 shares of Novatel stock for almost $29 million in proceeds. (Id. at ¶ 15.) Plaintiffs allege that 62% of the Defendants’ Class Period sales occurred in June and July 2007, just before the market learned about these concealed facts. (Id. at ¶ 16.) Plaintiffs claim that four specific stock price declines on July 20, 2007, February 21, 2008, April 15, 2008, and August 20, 2008, resulted from the market learning of these allegedly concealed facts. (Id. at ¶¶ 125-28.)

Legal Standard

Federal Rule of Evidence 702 provides that expert testimony is admissible if “scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue.” Fed.R.Evid. 702. Expert testimony under Rule 702 must be both relevant and reliable. Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 589, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). When considering evidence proffered under Rule 702, the trial court must act as a “gatekeeper” by making a preliminary determination that the expert’s proposed testimony is reliable. Elsayed Mukhtar v. Cal. State Univ., Hayward, 299 F.3d 1053, 1063 (9th Cir.2002), amended by 319 F.3d 1073 (9th Cir.2003).

As a guide for assessing the scientific validity of expert testimony, the Supreme Court provided a non-exhaustive list of factors that courts may consider: (1) whether the theory or technique is gener[1213]*1213ally accepted within a relevant scientific community, (2) whether the theory or technique has been subjected to peer review and publication, (3) the known or potential rate of error, and (4) whether the theory or technique can be tested. Daubert, 509 U.S. at 593-94, 113 S.Ct. 2786; see also Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999). The Ninth Circuit also has indicated that independent research, rather than research conducted for the purposes of litigation, carries with it the indicia of reliability. See Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311, 1317 (9th Cir.1995) (“Daubert II”). In particular, using independent, pre-existing research “provides objective proof that the research comports with the dictates of good science” and is less likely “to have been biased by the promise of remuneration.” "Id. If the testimony is not based on “pre-litigation” research or if the expert’s research has not been subjected to peer review, then the expert must explain precisely how he went about reaching his conclusions and point to some objective source — a learned treatise, the policy statement of a professional association, a published article in a reputable scientific journal or the like, to show that he has followed the scientific method, as it is practiced by (at least) a recognized minority of scientists in his field. Id. at 1318-19 (citing United States v. Rincon, 28 F.3d 921, 924 (9th Cir.1994)); see also Lust v. Merrell Dow Pharmaceuticals, Inc., 89 F.3d 594, 597 (9th Cir.1996). The proponent of the evidence must prove its admissibility by a preponderance of proof. See Daubert, 509 U.S. at 593 n. 10, 113 S.Ct. 2786.

Discussion

Defendants have filed a motion seeking to exclude the testimony of Plaintiffs’ loss causation expert, Bjorn Steinholt, as inadmissible under Rule 702 of the Federal Rules of Evidence as well as Daubert and its progeny. (Defs.’ Mot., Doc. No. 299-1.) Among other things, Defendants contend primarily that: (1) Steinholt’s opinions on loss causation are based on a defective event study, and (2) Steinholt’s damages calculations cannot be reconciled with Dura Pharms., Inc. v. Broudo, 544 U.S. 336, 125 S.Ct. 1627, 161 L.Ed.2d 577 (2005), and subsequent Ninth Circuit case law. (Id.)

A. Steinholt’s Opinion Regarding Loss Causation

1. Loss Causation Generally

In order to succeed on a private right of action brought pursuant to Section 10(b) of the Securities and Exchange Act, a plaintiff must prove, inter alia, loss causation. See Stoneridge Inv. Partners, LLC v. Scientific-Atlanta, Inc., 552 U.S. 148, 156-57, 128 S.Ct. 761, 169 L.Ed.2d 627 (2008).

Free access — add to your briefcase to read the full text and ask questions with AI

In re Novatel Wireless Securities Litigation, 910 F. Supp. 2d 1209, 2012 WL 6644279 (S.D. Cal. 2012).

910 F. Supp. 2d 1209 (In re Novatel Wireless Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Cooper v. Federal Reserve Bank of Richmond
467 U.S. 867 (Supreme Court, 1984)
Bazemore v. Friday
478 U.S. 385 (Supreme Court, 1986)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
In Re Williams Securities Litigation-WCG Subclass
558 F.3d 1130 (Tenth Circuit, 2009)
In Re Oracle Corp. Securities Litigation
627 F.3d 376 (Ninth Circuit, 2010)
United States v. Hiram Webb
655 F.2d 977 (Ninth Circuit, 1981)
United States v. Hugo Rincon
28 F.3d 921 (Ninth Circuit, 1994)
Mukhtar v. California State University, Hayward
319 F.3d 1073 (Ninth Circuit, 2003)
Metzler Investment GMBH v. Corinthian Colleges, Inc.
540 F.3d 1049 (Ninth Circuit, 2008)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
In Re Remec Incorporated Securities Litigation
702 F. Supp. 2d 1202 (S.D. California, 2010)
In Re Williams Securities Litigation
496 F. Supp. 2d 1195 (N.D. Oklahoma, 2007)